Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at CHF 7.7B, ahead of BioNTech (CHF 7.2B) and Gilead Sciences (CHF 6.4B). Figures as of 19 Nov 2026, 01:28 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenCHF 7.7B
- Median
- CHF 364.9M
- Combined market value
- CHF 704.7B
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 7.7B | CHF 202.3B | CHF 374.00 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | CHF 7.2B | CHF 17.4B | CHF 70.15 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | CHF 6.4B | CHF 176.6B | CHF 142.37 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | CHF 2.9B | CHF 49.9B | CHF 793.04 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | CHF 2.5B | CHF 31.3B | CHF 211.82 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | CHF 2.2B | CHF 67.1B | CHF 165.80 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | CHF 760.1M | CHF 5.8B | CHF 27.95 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | CHF 706.9M | CHF 8.6B | CHF 41.76 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | CHF 600.7M | CHF 13.9B | CHF 137.22 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | CHF 476.9M | CHF 9.3B | CHF 145.48 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | CHF 418.2M | CHF 7.9B | CHF 265.69 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | CHF 406.5M | CHF 14B | CHF 57.54 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | CHF 323.3M | CHF 29.1B | CHF 134.65 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | CHF 300.8M | CHF 8.7B | CHF 102.06 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | CHF 292.8M | CHF 3.3B | CHF 33.86 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | CHF 272.6M | CHF 4.9B | CHF 40.44 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | CHF 223M | CHF 9.6B | CHF 61.29 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | CHF 176.8M | CHF 5.4B | CHF 82.41 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | CHF 154.2M | CHF 6.7B | CHF 98.03 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | CHF 146.6M | CHF 7.8B | CHF 49.31 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | CHF 112.7M | CHF 9.2B | CHF 80.72 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | CHF 74.4M | CHF 6B | CHF 5.65 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | CHF 59.4M | CHF 3.9B | CHF 23.98 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | CHF 27.4M | CHF 6B | CHF 67.40 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8425 CHF).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (CHF 7.7B), BioNTech (CHF 7.2B) and Gilead Sciences (CHF 6.4B) are the top three of the 24 biotech companies ranked by cash on hand as of 19 Nov 2026, 01:28 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of CHF 704.7B as of 19 Nov 2026, 01:28 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 19 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.